S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a.
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Epithelial-Mesenchymal Transition
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
MicroRNAs
/ genetics
S-Adenosylmethionine
/ pharmacology
Triple Negative Breast Neoplasms
/ genetics
Up-Regulation
/ drug effects
S-Adenosylmethionine
cancer therapy
cell growth and migration
miRNA-34c
miRNA-449a
microRNA
triple negative breast cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Dec 2020
30 Dec 2020
Historique:
received:
30
11
2020
revised:
19
12
2020
accepted:
25
12
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is one of the most common malignancies worldwide and shows maximum invasiveness and a high risk of metastasis. Recently, many natural compounds have been highlighted as a valuable source of new and less toxic drugs to enhance breast cancer therapy. Among them, S-adenosyl-L-methionine (AdoMet) has emerged as a promising anti-cancer agent. MicroRNA (miRNA or miR)-based gene therapy provides an interesting antitumor approach to integrated cancer therapy. In this study, we evaluated AdoMet-induced modulation of miRNA-34c and miRNA-449a expression in MDA-MB-231 and MDA-MB-468 TNBC cells. We demonstrated that AdoMet upregulates miR-34c and miR-449a expression in both cell lines. We found that the combination of AdoMet with miR-34c or miR-449a mimic strongly potentiated the pro-apoptotic effect of the sulfonium compound by a caspase-dependent mechanism. For the first time, by video time-lapse microscopy, we showed that AdoMet inhibited the in vitro migration of MDA-MB-231 and MDA-MB-468 cells and that the combination with miR-34c or miR-449a mimic strengthened the effect of the sulfonium compound through the modulation of β-catenin and Small Mother Against Decapentaplegic (SMAD) signaling pathways. Our results furnished the first evidence that AdoMet exerts its antitumor effects in TNBC cells through upregulating the expression of miR-34c and miR-449a.
Identifiants
pubmed: 33396625
pii: ijms22010286
doi: 10.3390/ijms22010286
pmc: PMC7795242
pii:
doi:
Substances chimiques
MIRN34 microRNA, human
0
MIRN449 microRNA, human
0
MicroRNAs
0
S-Adenosylmethionine
7LP2MPO46S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS One. 2015 Feb 06;10(2):e0117097
pubmed: 25658419
Oncotarget. 2014 May 15;5(9):2736-49
pubmed: 24811362
Mol Carcinog. 2013 Apr;52(4):318-27
pubmed: 22213190
Anticancer Drugs. 2017 Nov;28(10):1067-1078
pubmed: 29023247
Cancers (Basel). 2018 Feb 16;10(2):
pubmed: 29462906
Int J Mol Sci. 2018 Nov 20;19(11):
pubmed: 30463358
PLoS One. 2013 Sep 30;8(9):e75628
pubmed: 24098708
Cell Death Dis. 2020 Oct 13;11(10):850
pubmed: 33051434
J Cell Physiol. 2016 Feb;231(2):428-35
pubmed: 26174106
Eur J Clin Invest. 2018 Apr;48(4):
pubmed: 29405291
Cancers (Basel). 2020 Dec 07;12(12):
pubmed: 33297397
J Biomed Sci. 2019 Jan 12;26(1):7
pubmed: 30634952
Int J Mol Sci. 2020 Nov 13;21(22):
pubmed: 33202711
Cancer Cell Int. 2018 Dec 4;18:197
pubmed: 30533999
J Fam Pract. 2002 May;51(5):425-30
pubmed: 12019049
J Cancer. 2018 Sep 28;9(20):3765-3775
pubmed: 30405848
Pharmacol Res. 2015 Jul;97:104-21
pubmed: 25958353
FEBS Lett. 2017 Mar;591(5):693-705
pubmed: 28192603
Nat Rev Clin Oncol. 2019 Jan;16(1):27-44
pubmed: 30206303
J Cancer. 2019 Jul 22;10(18):4368-4379
pubmed: 31413757
J Clin Invest. 2013 Jan;123(1):285-98
pubmed: 23241961
Breast Cancer Res. 2019 Feb 6;21(1):21
pubmed: 30728048
J Hepatol. 2017 May;66(5):1012-1021
pubmed: 28088579
Int J Oncol. 2020 May;56(5):1212-1224
pubmed: 32319579
Oncol Rep. 2014 Sep;32(3):1193-9
pubmed: 24993091
Oncogene. 2013 Sep 5;32(36):4294-303
pubmed: 23001043
J Biol Chem. 2004 Jul 23;279(30):31735-44
pubmed: 15150277
Genet Mol Res. 2013 Apr 10;12(2):1106-18
pubmed: 23661436
Histopathology. 2008 Jan;52(1):108-18
pubmed: 18171422
BMC Cancer. 2014 Jul 26;14:538
pubmed: 25064703
Pathol Res Pract. 2018 May;214(5):790-795
pubmed: 29653747
Yonsei Med J. 2017 Jul;58(4):697-702
pubmed: 28540980
Int J Mol Sci. 2019 Sep 24;20(19):
pubmed: 31554177
DNA Cell Biol. 2019 Feb;38(2):198-207
pubmed: 30570350
BMC Med. 2019 May 9;17(1):90
pubmed: 31068190
Can J Psychiatry. 2012 Jul;57(7):406-13
pubmed: 22762295
Cells. 2019 Nov 22;8(12):
pubmed: 31766744
Molecules. 2016 Jul 22;21(7):
pubmed: 27455225
Oncotarget. 2015 Jun 30;6(18):15966-83
pubmed: 25965826
Int J Biochem Cell Biol. 2000 Apr;32(4):391-5
pubmed: 10762064
Oncotarget. 2018 Apr 10;9(27):18929-18938
pubmed: 29721173
Breast Cancer (Auckl). 2015 Sep 01;9(Suppl 1):23-34
pubmed: 26380552
Mol Cancer. 2010 Jul 07;9:179
pubmed: 20609236
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Int J Clin Exp Med. 2014 Jan 15;7(1):32-40
pubmed: 24482686
J Hepatol. 2012 Nov;57(5):1097-109
pubmed: 22659519
Cell Mol Biol (Noisy-le-grand). 2015 Oct 16;61(5):1-10
pubmed: 26475381
Cells. 2020 Aug 09;9(8):
pubmed: 32784836
Curr Top Med Chem. 2019;19(31):2816-2823
pubmed: 31755392
J Struct Biol. 2020 Apr 1;210(1):107462
pubmed: 31962159
Oncotarget. 2016 Apr 5;7(14):18906-18
pubmed: 26934316
Bone Res. 2020 Jul 22;8:28
pubmed: 32714613
Cancer Res. 2006 Sep 15;66(18):9202-10
pubmed: 16982764
J Cell Physiol. 2019 Aug;234(8):13277-13291
pubmed: 30575033
J Zhejiang Univ Sci B. 2020 Sept.;21(9):673-689
pubmed: 32893525
Endocrine. 2015 Sep;50(1):212-22
pubmed: 25577236
Physiol Rev. 2012 Oct;92(4):1515-42
pubmed: 23073625
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
J Cell Physiol. 2018 Feb;233(2):1370-1383
pubmed: 28518408
Mol Biol Cell. 2005 Apr;16(4):1987-2002
pubmed: 15689496
Nature. 2019 Sep;573(7774):439-444
pubmed: 31485072
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Front Oncol. 2019 Oct 04;9:989
pubmed: 31637214
Mol Oncol. 2015 Mar;9(3):640-56
pubmed: 25487955
Oncol Res. 2019 Feb 5;27(2):227-235
pubmed: 29562957
Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622
pubmed: 30683944
Cancer Med. 2015 May;4(5):732-44
pubmed: 25619880
J Cell Mol Med. 2020 Sep;24(18):10322-10337
pubmed: 32720467
Oncol Res. 2017 May 24;25(5):753-761
pubmed: 27983918
World J Gastroenterol. 2020 Sep 14;26(34):5101-5117
pubmed: 32982112
Oncotarget. 2017 Dec 26;9(4):5169-5183
pubmed: 29435170
Mayo Clin Proc. 2018 Jun;93(6):794-807
pubmed: 29866283
Front Oncol. 2020 Aug 07;10:1513
pubmed: 32903818
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Sci Rep. 2020 Sep 28;10(1):15921
pubmed: 32985606
Mol Ther Nucleic Acids. 2020 Jun 5;20:711-724
pubmed: 32402942
J Exp Clin Cancer Res. 2019 Feb 4;38(1):53
pubmed: 30717802
Cancer Metastasis Rev. 2015 Mar;34(1):145-55
pubmed: 25721950
Mol Oncol. 2017 Jan;11(1):28-39
pubmed: 28085222
BMC Cancer. 2019 Jun 14;19(1):581
pubmed: 31200666
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1656-1665
pubmed: 32141531